Rein therapeutics presents two posters at the american thoracic society 2025 international conference

Presentations further support the dual mechanism of lti-03 and the development of cav1-related peptides for the treatment of idiopathic pulmonary fibrosis (ipf) company recently initiated renew phase 2 trial evaluating the safety, tolerability and efficacy of lti-03 in ipf austin, texas , may 19, 2025 /prnewswire/ -- rein therapeutics ("rein") (nasdaq: rntx), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the company and its collaborators presented two posters supporting the potential therapeutic effectiveness of lti-03 in idiopathic pulmonary fibrosis (ipf) at the american thoracic society (ats) 2025 international conference. "the presentations delivered at ats today provide further support for the dual mechanism of our lead asset, lti-03, which has demonstrated sustained alveolar epithelial cell survival as well as inhibition of profibrotic signaling," said cory hogaboam, ph.d.
RNTX Ratings Summary
RNTX Quant Ranking